Surbhi Sidana, MD
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sidana’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A162790 · Current
Licensed to practise in California · since 2019 · expires 2027-05-31 · University of Delhi, Maulana Azad Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$34,468
Medicare paid this office $34,468 for 76 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $13,306 | $106 |
| Long return visit (40+ min) | 35 | $11,244 | $131 |
| Long return visit (40+ min) | 17 | $3,441 | $164 |
| New patient visit (60+ min) | 18 | $2,940 | $163 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,154 | $105 |
Who their Medicare patients are
76 Original Medicare patients in 2024. Average age 70 · Women 57% · Also on Medicaid 22% · Health risk score 2.93. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 61% · Chronic kidney disease 26% · Diabetes 25% · Coronary heart disease 24% · Atrial fibrillation 21% · Heart failure 17% · Cancer 17% · Depression 16%.
The office billed $108,905, Medicare allowed $43,741 and paid $34,468; for 281 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 76 | 281 | 70 | 2.93 | $108,905 | $34,468 |
| 2023 | 63 | 275 | 69 | 3.30 | $111,423 | $32,496 |
| 2022 | 42 | 134 | 69 | 2.85 | $66,362 | $15,595 |
| 2021 | 44 | 209 | 68 | 2.80 | $101,265 | $23,407 |
| 2020 | 75 | 312 | 67 | 3.29 | $167,752 | $32,970 |
| 2019 | 32 | 60 | 69 | 1.86 | $9,092 | $6,423 |
| 2018 | 44 | 73 | 74 | 2.55 | $14,595 | $6,890 |
| 2017 | 40 | 93 | 71 | 1.60 | $11,683 | $7,485 |
| 2016 | 51 | 112 | 71 | 1.56 | $14,785 | $9,841 |
| 2015 | 20 | 27 | 73 | 1.90 | $4,070 | $2,828 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $16,894 | $110 |
| Long return visit (40+ min) | 28 | $8,976 | $136 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,759 | $160 |
| Return visit (30+ min) | 15 | $1,716 | $86 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,392 | $107 |
2022: 2 services
| Long return visit (40+ min) | 25 | $6,897 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $5,466 | $94 |
2021: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $9,641 | $95 |
| Long return visit (40+ min) | 23 | $7,675 | $120 |
| Return visit (30+ min) | 11 | $1,101 | $85 |
2020: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $14,785 | $98 |
| Long return visit (40+ min) | 38 | $11,645 | $103 |
2019: 1 service
| Return visit (30+ min) | 17 | $2,364 | $84 |
2018: 2 services
| Return visit (30+ min) | 31 | $3,125 | $73 |
| Long return visit (40+ min) | 16 | $2,385 | $114 |
2017: 1 service
| Return visit (30+ min) | 34 | $5,515 | $75 |
2016: 2 services
| Return visit (30+ min) | 30 | $4,451 | $75 |
| Long return visit (40+ min) | 22 | $3,630 | $107 |
2015: 1 service
| Long return visit (40+ min) | 12 | $1,558 | $111 |
Medicaid work
$1,216 in 2024
Medicaid paid $1,216 for 15 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 15 | $1,216 |
| 2024 | 15 | 1 | 12 | $1,216 |
| 2023 | 24 | 1 | 12 | $1,580 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 24 | $1,580 |
Drugs they prescribed that Part D paid
$79,318
Pharmacies billed $79,318 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
226 generic and 13 brand-name prescriptions · $79,318 in drug cost · 44 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Atovaquone | 18 | $7,693 | $427 |
| Acyclovir | 75 | $1,722 | $23 |
| Sulfamethoxazole-Trimethoprim | 31 | $225 | $7 |
| Levofloxacin | 11 | $145 | $13 |
| Ondansetron | 15 | $109 | $7 |
See all 6 drugs
| Atovaquone | 18 | $7,693 | $427 |
| Acyclovir | 75 | $1,722 | $23 |
| Sulfamethoxazole-Trimethoprim | 31 | $225 | $7 |
| Levofloxacin | 11 | $145 | $13 |
| Ondansetron | 15 | $109 | $7 |
| Lorazepam | 12 | $76 | $6 |
Year by year
| 2024 | 239 | 36 | None | 5% | $79,318 |
| 2023 | 189 | 32 | 0% (0) | None | $180,415 |
| 2022 | 125 | 27 | 0% (0) | None | $17,669 |
| 2021 | 159 | 27 | 7% (11) | 9% | $97,927 |
| 2020 | 76 | 16 | 0% (0) | None | $51,919 |
| 2019 | 42 | None | 0% (0) | None | $60,848 |
| 2018 | 82 | 19 | None | 28% | $297,333 |
| 2017 | 100 | 22 | None | 33% | $344,634 |
| 2016 | 129 | 45 | None | 17% | $104,615 |
| 2015 | 207 | 39 | None | None | $12,833 |
| 2014 | 240 | 51 | None | None | $12,313 |
| 2013 | 106 | 23 | None | None | $3,933 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Acyclovir | 41 | $1,305 | $32 |
| Sulfamethoxazole-Trimethoprim | 50 | $632 | $13 |
2022: 4 drugs
| Acyclovir | 35 | $927 | $26 |
| Sulfamethoxazole-Trimethoprim | 21 | $201 | $10 |
| Ondansetron | 13 | $94 | $7 |
| Lorazepam | 11 | $71 | $6 |
2021: 3 drugs
| Acyclovir | 36 | $1,019 | $28 |
| Entecavir | 14 | $434 | $31 |
| Sulfamethoxazole-Trimethoprim | 18 | $118 | $7 |
2020: 1 drug
| Acyclovir | 15 | $233 | $16 |
2018: 1 drug
| Revlimid | 13 | $192,242 | $14,788 |
2017: 2 drugs
| Jakafi | 12 | $140,278 | $11,690 |
| Dexamethasone | 12 | $188 | $16 |
2016: 2 drugs
| Dexamethasone | 17 | $226 | $13 |
| Sulfamethoxazole-Trimethoprim | 16 | $116 | $7 |
2015: 4 drugs
| Atorvastatin | 11 | $242 | $22 |
| Losartan | 11 | $206 | $19 |
| Amlodipine Besylate | 22 | $144 | $7 |
| Pantoprazole | 13 | $71 | $5 |
2014: 3 drugs
| Pantoprazole | 16 | $378 | $24 |
| Atorvastatin | 13 | $343 | $26 |
| Metformin | 13 | $60 | $5 |
Money from drug and device companies
$61,369 in 2025
| 2025 | 9 | 49 | $58,077 | $61,369 |
| 2024 | 14 | 52 | $34,185 | $41,873 |
| 2023 | 13 | 44 | $34,478 | $38,127 |
| 2022 | 5 | 21 | $16,475 | $17,176 |
| 2021 | 3 | 3 | $6,031 | $6,031 |
| 2020 | 1 | 1 | $2,640 | $2,640 |
| 2019 | 2 | 7 | $990 | $2,327 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Elrexfio | $23,500 | 5 payments
|
| Janssen Biotech | Darzalex | $11,455 | 15 payments
|
| Janssen Global Services | Darzalex | $9,312 | 17 payments
|
| Legend Biotech USA | Carvykti | $6,555 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | None | $3,840 | 2 payments
|
| Regeneron Pharmaceuticals | Lynozyfic | $2,909 | 1 payment
|
See all 49 published payments
| Janssen Global Services | Meals · 2025-12-06 | Carvykti | $85 |
| Janssen Global Services | Meals · 2025-12-05 | Darzalex | $39 |
| Celgene | Meals · 2025-12-05 | None | $65 |
| Pfizer | Consulting · 2025-10-24 | Elrexfio | $13,200 |
| Janssen Global Services | Consulting · 2025-10-03 | Darzalex | $2,160 |
| Legend Biotech USA | Consulting · 2025-09-25 | Carvykti | $6,325 |
| Legend Biotech USA | Meals · 2025-09-25 | Carvykti | $125 |
| Pfizer | Consulting · 2025-09-24 | Elrexfio | $600 |
| Janssen Biotech | Meals · 2025-09-19 | Darzalex | $32 |
| Regeneron Pharmaceuticals | Consulting · 2025-09-19 | Lynozyfic | $2,909 |
| Janssen Global Services | Travel · 2025-09-15 | Darzalex | $10 |
| Janssen Global Services | Consulting · 2025-09-15 | Darzalex | $1,080 |
| Janssen Global Services | Meals · 2025-09-15 | Darzalex | $12 |
| Janssen Global Services | Meals · 2025-09-15 | Darzalex | $59 |
| Janssen Global Services | Travel · 2025-09-15 | Darzalex | $10 |
| Janssen Global Services | Meals · 2025-09-15 | Darzalex | $19 |
| Janssen Global Services | Travel · 2025-09-14 | Darzalex | $275 |
| Pfizer | Consulting · 2025-09-04 | Elrexfio | $900 |
| Janssen Global Services | Travel · 2025-08-13 | Darzalex | $269 |
| Janssen Biotech | Consulting · 2025-07-25 | None | $1,800 |
| Pfizer | Consulting · 2025-07-23 | Elrexfio | $4,500 |
| Janssen Scientific Affairs | Consulting · 2025-07-01 | None | $971 |
| Janssen Global Services | Consulting · 2025-06-27 | Darzalex | $2,160 |
| Janssen Biotech | Meals · 2025-06-14 | Talvey | $93 |
| Janssen Global Services | Meals · 2025-06-12 | Darzalex | $18 |
| Janssen Global Services | Travel · 2025-06-12 | Darzalex | $55 |
| Janssen Global Services | Meals · 2025-06-12 | Darzalex | $23 |
| Legend Biotech USA | Meals · 2025-06-09 | None | $7 |
| Legend Biotech USA | Travel · 2025-06-09 | None | $7 |
| Legend Biotech USA | Meals · 2025-06-02 | Carvykti | $91 |
| Celgene | Meals · 2025-05-28 | Breyanzi | $223 |
| Pfizer | Consulting · 2025-05-22 | Elrexfio | $4,300 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-04-08 | None | $975 |
| Janssen Biotech | Meals · 2025-03-05 | Darzalex | $66 |
| Janssen Biotech | Travel · 2025-03-04 | Darzalex | $279 |
| Janssen Biotech | Consulting · 2025-03-04 | Darzalex | $7,755 |
| Janssen Biotech | Travel · 2025-03-04 | Darzalex | $140 |
| Janssen Biotech | Travel · 2025-03-04 | Darzalex | $8 |
| Janssen Biotech | Travel · 2025-03-04 | Darzalex | $13 |
| Janssen Biotech | Travel · 2025-03-03 | Darzalex | $80 |
| Janssen Biotech | Travel · 2025-03-03 | Darzalex | $150 |
| Janssen Biotech | Travel · 2025-03-03 | Darzalex | $52 |
| Janssen Biotech | Travel · 2025-03-03 | Darzalex | $945 |
| Janssen Biotech | Meals · 2025-03-03 | Darzalex | $33 |
| Janssen Biotech | Travel · 2025-03-03 | Darzalex | $8 |
| Gilead Sciences | Consulting · 2025-02-10 | None | $2,540 |
| Janssen Global Services | Consulting · 2025-01-10 | Darzalex | $675 |
| Janssen Global Services | Consulting · 2025-01-10 | Darzalex | $2,363 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-01-08 | None | $2,865 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $41,873
| Regeneron Pharmaceuticals | None | $14,943 | 15 payments
|
| Janssen Global Services | Darzalex | $7,318 | 10 payments
|
| Kite Pharma | None | $4,120 | 3 payments
|
| F. Hoffmann-La Roche AG | None | $3,148 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $2,692 | 5 payments
|
| Gilead Sciences | None | $2,540 | 1 payment
|
| Abbvie | None | $2,200 | 1 payment
|
| BioLineRx USA | Aphexda | $1,563 | 1 payment
|
| Janssen Scientific Affairs | Carvykti | $1,090 | 1 payment
|
| Pfizer | Elrexfio | $783 | 3 payments
|
| Genentech USA | None | $625 | 1 payment
|
| Celgene | Abecma | $596 | 5 payments
|
| Janssen Biotech | Darzalex | $130 | 2 payments
|
| Genentech | None | $126 | 1 payment
|
2023: $38,127
| Legend Biotech USA | Carvykti | $8,826 | 10 payments
|
| E.R. Squibb & Sons L.L.C. | None | $8,792 | 5 payments
|
| Pfizer | Elrexfio | $5,439 | 6 payments
|
| Janssen Global Services | Carvykti | $4,379 | 9 payments
|
| Kite Pharma | Tecartus | $3,820 | 1 payment
|
| Janssen Biotech | Tecvayli | $2,475 | 2 payments
|
| Janssen Scientific Affairs | None | $2,180 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $1,609 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $238 | 1 payment
|
| F. Hoffmann-La Roche AG | None | $136 | 1 payment
|
| Celgene | None | $129 | 4 payments
|
| Genzyme | None | $84 | 1 payment
|
| Janssen Research & Development | None | $20 | 1 payment
|
2022: $17,176
| E.R. Squibb & Sons L.L.C. | Abecma | $10,144 | 7 payments
|
| Janssen Biotech | Darzalex | $4,966 | 6 payments
|
| Janssen Scientific Affairs | None | $930 | 1 payment
|
| Genzyme | Sarclisa | $749 | 1 payment
|
| Celgene | Abecma | $386 | 6 payments
|
2021: $6,031
| Genzyme | Sarclisa | $2,187 | 1 payment
|
| Celgene | Abecma | $2,076 | 1 payment
|
| Janssen Biotech | Darzalex | $1,768 | 1 payment
|
2020: $2,640
| Janssen Scientific Affairs | None | $2,640 | 1 payment
|
2019: $2,327
| Janssen Biotech | Darzalex | $2,267 | 6 payments
|
| Novartis Pharmaceuticals | Kymriah | $61 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Kite Pharma, Inc. · Identifying Determinants of Response, Resistance and Toxicity With Car-T Therapy and Bispecific Antibodies in Multiple Myeloma To Mitigate Toxicity and Optimize the Sequencing of Immunotherpy in Multiple Myeloma · 2025 | Their institution | $250,000 |
| Celgene Corporation · A Phase 1, Open-Label, Dose-Finding Study of Bms-986453, Dual Targeting Bcmaxgprc5d Chimeric Antigen Receptor T Cells, in Participants With Relapsed and Or Refractory Multiple Myeloma. · 2025 | Their institution | $223,415 |
| E.R. Squibb & Sons, L.L.C. · A Phase 1, Open-Label, Dose-Finding Study of Bms-986453, Dual Targeting Bcmaxgprc5d Chimeric Antigen Receptor T Cells, in Participants With Relapsed and Or Refractory Multiple Myeloma. · 2025 | Their institution | $205,501 |
| Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64007957 A Humanized Bcma X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2021 | Their institution | $189,700 |
| Novartis Pharmaceuticals Corporation · Phase II, Open Label, Study of Phe885, A B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma · 2023 | Their institution | $154,439 |
| Janssen Research & Development, LLC · A Phase 2 Multicohort Open Label Study of Jnj68284528 A Chimeric Antigen Receptor T Cell Cart Therapy Directed Against Bcma in Subjects With Multiple Myeloma · 2021 | Their institution | $135,732 |
| Janssen Research & Development, LLC · A Safety and Efficacy Study of Jnj-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (Oos) for Commercial Release in Patients With Multiple Myeloma · 2023 | Their institution | $130,207 |
| Janssen Research & Development, LLC · A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab Sc (Tec-Dara) Versus Daratumumab Sc, Pomalidomide, and Dexamethasone (Dpd) Or Daratumumab Sc, Bortezomib, and Dexamethasone (Dvd) in Participants With Relapsed Or Refractory · 2024 | Their institution | $123,217 |
| Novartis Pharmaceuticals Corporation · Phase II, Open Label, Study of Phe885, A B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma · 2024 | Their institution | $121,143 |
| Janssen Research & Development, LLC · A Phase 2 Multicohort Open Label Study of Jnj68284528 A Chimeric Antigen Receptor T Cell Cart Therapy Directed Against Bcma in Subjects With Multiple Myeloma · 2022 | Their institution | $119,087 |
| Janssen Research & Development, LLC · A Phase 2 Multicohort Open Label Study of Jnj68284528 A Chimeric Antigen Receptor T Cell Cart Therapy Directed Against Bcma in Subjects With Multiple Myeloma · 2023 | Their institution | $109,072 |
| Janssen Research & Development, LLC · A Safety and Efficacy Study of Jnj-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (Oos) for Commercial Release in Patients With Multiple Myeloma · 2024 | Their institution | $107,764 |
| Janssen Research & Development, LLC · A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab Sc (Tec-Dara) Versus Daratumumab Sc, Pomalidomide, and Dexamethasone (Dpd) Or Daratumumab Sc, Bortezomib, and Dexamethasone (Dvd) in Participants With Relapsed Or Refractory Multiple Myeloma Majestec-3 · 2023 | Their institution | $94,909 |
| Janssen Research & Development, LLC · An Open-Label, Non-Randomized, Phase 2 Study To Study the Efficacy of Talquetamab (Jnj-64407564) and Lenalidomide As Post Stem Cell Transplant Maintenance in Multiple Myeloma (Optimmal) · 2025 | Their institution | $90,048 |
| Janssen Research & Development, LLC · A Phase 2 Multicohort Open Label Study of Jnj68284528 A Chimeric Antigen Receptor T Cell Cart Therapy Directed Against Bcma in Subjects With Multiple Myeloma · 2025 | Their institution | $87,824 |
| Janssen Research & Development, LLC · A Safety and Efficacy Study of Jnj-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (Oos) for Commercial Release in Patients With Multiple Myeloma · 2022 | Their institution | $80,820 |
| Novartis Pharmaceuticals Corporation · Phase II, Open Label, Study of Phe885, A B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma · 2025 | Their institution | $69,381 |
| Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64007957 A Humanized Bcma X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2024 | Their institution | $64,091 |
| Janssen Research & Development, LLC · A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab Sc (Tec-Dara) Versus Daratumumab Sc, Pomalidomide, and Dexamethasone (Dpd) Or Daratumumab Sc, Bortezomib, and Dexamethasone (Dvd) in Participants With Relapsed Or Refractory Multiple Myeloma Majestec-3 · 2022 | Their institution | $54,345 |
| Janssen Research & Development, LLC · A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab Sc (Tec-Dara) Versus Daratumumab Sc, Pomalidomide, and Dexamethasone (Dpd) Or Daratumumab Sc, Bortezomib, and Dexamethasone (Dvd) in Participants With Relapsed Or Refractory · 2025 | Their institution | $53,037 |
| National Marrow Donor Program · Mm Car-T To Upgrade Response - Phase II Multicenter Trial of Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients With Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide · 2024 | Their institution | $50,504 |
| Janssen Research & Development, LLC · A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab Sc (Tec-Dara) Versus Daratumumab Sc, Pomalidomide, and Dexamethasone (Dpd) Or Daratumumab Sc, Bortezomib, and Dexamethasone (Dvd) in Participants With Relapsed Or Refractory · 2023 | Their institution | $48,093 |
| Celgene Corporation · Ct Dual Targeting Bcmaxgprc5d Phase I Esc/Exp Fih/Poc/Reg Study · 2024 | Their institution | $37,688 |
| Janssen Research & Development, LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Jnj-64007957, A Humanized Bcma X Cd3 Duobody Antibody, in Subjects With Relapsed Or Refractory Multiple Myeloma · 2025 | Their institution | $33,450 |
| National Marrow Donor Program · Mm Car-T To Upgrade Response - Phase II Multicenter Trial of Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients With Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenanc · 2022 | Their institution | $31,524 |
| Celgene Corporation · Expanded Access Protocol (Eap) for Patients Receiving Idecabtagene Vicleucel (Ide-Cel) That Is Non-Conforming for Commercial Release · 2022 | Their institution | $31,078 |
| Janssen Research & Development, LLC · Carvykti · 2024 | Their institution | $29,311 |
| Janssen Research & Development, LLC · A Phase 2 Multicohort Open Label Study of Jnj68284528 A Chimeric Antigen Receptor T Cell Cart Therapy Directed Against Bcma in Subjects With Multiple Myeloma · 2024 | Their institution | $24,831 |
| Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64007957 A Humanized Bcma X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2023 | Their institution | $19,296 |
| ABBVIE INC. · A Study To Assess Change in Disease Activity and Adverse Events (Ae)S in Adult Participants With Immunoglobulin Light Chain (Al) Amyloidosis Receiving Abbv-383 As An Intravenous (IV) Infusion · 2024 | Their institution | $18,880 |
| Janssen Research & Development, LLC · A Long-Term Study for Participants Previously Treated With Ciltacabtagene Autoleucel · 2025 | Their institution | $18,296 |
| ABBVIE INC. · A Study To Assess Change in Disease Activity and Adverse Events (Ae)S in Adult Participants With Immunoglobulin Light Chain (Al) Amyloidosis Receiving Abbv-383 As An Intravenous (IV) Infusion · 2025 | Their institution | $17,831 |
| Janssen Research & Development, LLC · A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab Sc (Tec-Dara) Versus Daratumumab Sc, Pomalidomide, and Dexamethasone (Dpd) Or Daratumumab Sc, Bortezomib, and Dexamethasone (Dvd) in Participants With Relapsed Or Refractory Multiple Myeloma Majestec-3 · 2025 | Their institution | $17,122 |
| Celgene Corporation · Expanded Access Protocol (Eap) for Patients Receiving Idecabtagene Vicleucel (Ide-Cel) That Is Non-Conforming for Commercial Release · 2023 | Their institution | $11,295 |
| Celgene Corporation · Expanded Access Protocol (Eap) for Patients Receiving Idecabtagene Vicleucel (Ide-Cel) That Is Non-Conforming for Commercial Release · 2024 | Their institution | $9,519 |
| Janssen Research & Development, LLC · Intermediate-Size Population Expanded Access Program (Eap) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (Oos) in Patients With Multiple Myeloma · 2024 | Their institution | $5,184 |
| Janssen Research & Development, LLC · A Phase 1 First in Human Open Label Dose Escalation Study of Jnj64007957 A Humanized Bcma X Cd3 Duobody Antibody in Subjects With Relapsed Or Refractory Multiple Myeloma · 2022 | Their institution | $3,712 |
| Celgene Corporation · Expanded Access Protocol (Eap) for Patients Receiving Idecabtagene Vicleucel (Ide-Cel) That Is Non-Conforming for Commercial Release · 2025 | Their institution | $3,520 |
| Janssen Research & Development, LLC · Intermediate-Size Population Expanded Access Program (Eap) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (Oos) in Patients With Multiple Myeloma · 2025 | Their institution | $1,600 |
| Novartis Pharmaceuticals Corporation · Phase II, Open Label, Study of Phe885, A B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma · 2022 | Their institution | $1,091 |
| Janssen Global Services, LLC · Carvykti · 2023 | This clinician | $450 |
Professional record
- NPI
- 1972868644
- Licence
- CA A162790, MN 59260California A162790: Current · expires 2027-05-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-07-09
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.